Australia markets closed

Arbutus Biopharma Corporation (ABUS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.3100-0.3000 (-6.51%)
At close: 04:00PM EST
4.2400 -0.07 (-1.62%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close4.6100
Bid4.2400 x 4000
Ask4.2900 x 1200
Day's range4.1100 - 5.2300
52-week range2.4300 - 6.5000
Avg. volume7,765,922
Market cap583.009M
Beta (5Y monthly)2.55
PE ratio (TTM)N/A
EPS (TTM)-0.9170
Earnings date02 Mar 2022 - 07 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.00
  • Motley Fool

    Why Moderna Stock Plunged Today

    What happened Shares of Moderna (NASDAQ: MRNA) fell 12% on Wednesday after a court ruling placed a portion of the biotech's blockbuster COVID-19 vaccine proceeds at risk. So what A U.S. Court of Appeals for the Federal Circuit panel affirmed a previous ruling by the U.

  • Motley Fool

    Why Arbutus Biopharma Is Rocketing Higher Today

    What happened Shares of Arbutus Biopharma (NASDAQ: ABUS) rocketed higher on Wednesday morning in response to a court ruling in its favor. The stock was up 70.2% at 11:41 a.m. on Wednesday. So what  Moderna's (NASDAQ: MRNA) attempt to avoid paying royalties on the lipid nanoparticle (LNP) technology that its COVID vaccine relies upon took another turn for the worse.

  • GlobeNewswire

    Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity

    WARMINSTER, Pa., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a broad portfolio of assets with different modes of action to provide a cure for people with chronic hepatitis B virus (cHBV) infection and to treat coronaviruses (including COVID-19), today announced preliminary data from its on-going Phase 1a/1b clinical trial demonstrating that its next gene